APDN Stock - Applied DNA Sciences, Inc.
Unlock GoAI Insights for APDN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.43M | $13.37M | $18.17M | $9.03M | $1.93M |
| Gross Profit | $1.02M | $5.53M | $5.05M | $4.93M | $1.21M |
| Gross Margin | 29.6% | 41.4% | 27.8% | 54.6% | 62.7% |
| Operating Income | $-14,024,765 | $-10,953,290 | $-13,969,763 | $-12,292,080 | $-12,535,000 |
| Net Income | $-6,992,521 | $-9,947,059 | $-8,377,996 | $-16,029,225 | $-12,764,974 |
| Net Margin | -203.8% | -74.4% | -46.1% | -177.6% | -660.9% |
| EPS | $-1.82 | $-15.21 | $-18.68 | $-46.35 | $-65.14 |
Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
Visit WebsiteEarnings History & Surprises
APDNEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 14, 2025 | $-37.50 | $-34.00 | +9.3% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-45.00 | $-230.13 | -411.4% | ✗ MISS |
Q1 2025 | Feb 13, 2025 | $-16.00 | $-28.00 | -75.0% | ✗ MISS |
Q4 2024 | Dec 17, 2024 | $-16.50 | $-16.00 | +3.0% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-32.00 | $23.50 | +173.4% | ✓ BEAT |
Q2 2024 | May 10, 2024 | $-230.00 | $-265.50 | -15.4% | ✗ MISS |
Q1 2024 | Feb 8, 2024 | $-310.00 | $-90.00 | +71.0% | ✓ BEAT |
Q4 2023 | Dec 7, 2023 | $-270.00 | $-260.00 | +3.7% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-240.00 | $-240.00 | 0.0% | = MET |
Q2 2023 | May 11, 2023 | $-170.00 | $-200.00 | -17.6% | ✗ MISS |
Q1 2023 | Feb 9, 2023 | $-330.00 | $-140.00 | +57.6% | ✓ BEAT |
Q4 2022 | Dec 14, 2022 | $-0.26 | $-0.01 | +96.2% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-360.00 | $-330.00 | +8.3% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-300.00 | $-280.00 | +6.7% | ✓ BEAT |
Q1 2022 | Feb 10, 2022 | $-190.00 | $-630.00 | -231.6% | ✗ MISS |
Q4 2021 | Dec 9, 2021 | $-320.00 | $-490.00 | -53.1% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-240.00 | $-460.00 | -91.7% | ✗ MISS |
Q2 2021 | May 13, 2021 | $-180.00 | $-330.00 | -83.3% | ✗ MISS |
Q1 2021 | Feb 11, 2021 | $-550.00 | $-620.00 | -12.7% | ✗ MISS |
Q4 2020 | Dec 17, 2020 | $-590.00 | $-820.00 | -39.0% | ✗ MISS |
Latest News
Applied DNA Sciences shares are trading higher after the company announced it closed its private investment in public equity financing which resulted in the gross proceeds of approximately $27 million. Also, the company purchased an additional 4,908 BNB tokens.
📈 PositiveApplied DNA Sciences Closes Up To $58M Private Placement; Initial BNB Holdings Valued At $17M+
📈 PositiveApplied DNA Sciences Says On Sept 30, Announced Restructuring Plan; Restructuring Plan Includes 60% Workforce Reduction; Estimates $1.4M Pre-Tax Charges For Reduction In Q1 2026
📉 NegativeApplied DNA Sciences shares are trading higher after the company announced it will change its ticker symbol on the Nasdaq to BNBX on October 7.
➖ NeutralApplied DNA Sciences To Change Nasdaq Ticker To 'BNBX' On October 7
➖ NeutralApplied DNA Sciences shares are trading lower, pulling back from Monday strength.
📉 NegativeApplied DNA Sciences Shares Resume Trade Then Again Halt On Circuit Breaker To The Upside, Stock Now Up 66.18%
📈 PositiveApplied DNA Sciences Shares Halted On Circuit Breaker To The Upside, Stock Now Up 23.43%
📈 PositiveApplied DNA Sciences shares are trading higher after the company announced a private placement of up to $58M to launch a BNB treasury strategy and appointed Anthony Scaramucci as an adviser.
📈 PositiveApplied DNA Sciences Appoints Anthony Scaramucci As Adviser
➖ NeutralApplied DNA Announces Judy Murrah Has Voluntarily Resigned From Her Role Of President And CEO, Will Remain The Chairperson Of The Board Until A Replacement Is Nominated And Appointed; Clay Shorrock As President And Chief Executive Officer, Effective Immediately.
➖ NeutralApplied DNA $58M PIPE Offerings Involves 4,730,178 Shares Of Common Stock And Common Warrants; A Cryptocurrency Offering Involving 3,334,471 Prefunded Warrants And Common Warrants; The Warrants In Both Offerings Have An Exercise Price Of $3.82 And A 5-Year Term
➖ NeutralApplied DNA Sciences Secures Up To $58M PIPE To Initiate BNB-Focused Digital Asset Strategy; Intends To Change Ticker To BNBX
📈 PositiveApplied DNA Showcases Synthetic DNA Platforms At mRNA And CAR-TCR Summits; Highlights IVT Kit And Phase I AML Trial Using LineaDNA-Based CAR-T Cells
📈 PositiveFrequently Asked Questions about APDN
What is APDN's current stock price?
What is the analyst price target for APDN?
What sector is Applied DNA Sciences, Inc. in?
What is APDN's market cap?
Does APDN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to APDN for comparison